Whalesbook
FDA Approves Famotidine Injection
Lupin Pharmaceuticals announced on May 13, 2026, that the U.S. Food and Drug Administration (FDA) approved its famotidine injection USP. This injectable, available in 20 mg/2 mL single-dose vials, is bioequivalent to Merck's Pepcid Injection. It is intended for hospitalized patients needing intravenous treatment for hypersecretory conditions or intractable ulcers, or as an alternative for those who cannot take oral medication. Manufactured at Lupin's facility in Nagpur, the injection is expected to generate approximately $8.7 million in U.S. sales annually. This move supports Lupin's strategy to focus on higher-margin, complex generics and injectables, shifting away from the highly competitive oral generics market.
Strong Financial Results Amid Stock Drop
The famotidine approval announcement followed strong financial results for Lupin's fourth quarter and full fiscal year 2026. In the January-March quarter, net profit surged by nearly 97% year-over-year to ₹1,460 crore, fueled by robust U.S. generics performance and global revenue growth. Total revenue for the quarter increased 31.9% to ₹7,475 crore. For the full fiscal year 2026, net profit grew 62.5% to ₹5,333 crore, with revenue up 23.1% to ₹27,958 crore. However, Lupin's stock closed down 1.36% on May 13, 2026, at ₹2,215.45. This muted reaction echoes previous market responses to approvals like Dapagliflozin tablets and Brivaracetam Oral Solution, suggesting investors are weighing the modest revenue potential of the new famotidine injection and broader U.S. market pressures.
U.S. Market Pressures and Lupin's Strategy
The Indian pharmaceutical sector is forecast to grow 7-9% in FY2026, driven by domestic demand and exports. However, the key U.S. generics market, a major revenue source for Indian companies, is projected to slow to 3-5% growth in FY2026 from nearly 10% in FY2025. This slowdown is attributed to rising pricing pressures and competition. The overall U.S. generic drug market is expected to reach $130-$150 billion by 2026, expanding at a CAGR of 3-5%. Lupin, with a P/E ratio of 19-24 and a market cap around ₹1.01 trillion, is focusing on complex generics and injectables, such as the famotidine injection. This strategy aims for more stable revenues in a segment with fewer competitors than the volatile oral generics market. Lupin competes in this space with companies like Sun Pharma, Dr. Reddy's, Cipla, and Zydus.
Risks and Analyst Caution
Persistent risks remain, including intense pricing pressure and regulatory scrutiny in the U.S. generics market, which can impact profitability. The $8.7 million estimated annual sales for the famotidine injection, while a positive contribution, are modest relative to Lupin's total revenue. Although Indian pharmaceutical exports show a strong overall outlook, the U.S. market faces challenges such as potential trade investigations and slowing growth. Analyst sentiment leans towards caution, with some reports suggesting 'Hold' ratings and price targets that acknowledge potential downside, with one bear case scenario at ₹1,600. Lupin's significant R&D investments for complex generics also represent a considerable ongoing cost.
Growth Prospects and Analyst Outlook
Analysts generally hold a constructive view on Lupin, with a consensus 'Moderate Buy' rating and average 12-month price targets between ₹2,400 and ₹2,700. The company's shift to complex generics, biosimilars, and injectables is considered a primary driver for future growth and improved margins. Management emphasizes the company's resilience and strategic investments in technology and operations. Lupin's success in securing diverse regulatory approvals and expanding its global presence, especially in high-value markets, will be key to navigating competition and delivering shareholder value.